GMEP方案治疗难治性或复发性非霍奇金淋巴瘤的近期疗效报告

GMEP REGIMEN IN THE TREATMENT OF RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA:A REPROT OF SHORT TERM EFFICACY

目的:评价GMEP方案治疗难治性或复发性非霍奇金淋巴瘤(non-Hodgkin’slymphoma,NHL)的近期疗效及不良反应。方法:30例难治性或复发性NHL患者接受GMEP方案化疗:健择(GEM)1000mg/m^2d_(1,8),静滴,米托蒽醌(MIT)6-8mg/m^2d_1,静滴,足叶乙甙(VP-16)60mg/m^2d_(1-5),静滴,强的松(PDN)60mg/m^2口服,d_(1-5)每3～4周重复。疗程不少于3个周期。结果:全组30例患者均按计划完成化疗。随诊率93.3%,中位生存期11.3个月,1年生存率为43.3%,2年生存率为30.8%。治疗后总缓解率为80%(24/30),其中CR6例(20%),PR18例(60%)。10例具有B类症状的患者中,6例症状消失,2例明显改善,2例无改善。化疗最常见的不良反应为骨髓抑制、胃肠道反应和肝功能损害。结论:GMEP方案治疗难治性或复发性NHL,近期疗效较好,毒性反应轻,患者可以耐受。

Objective： To evaluate the therapeutic effect and toxicity of GMEP regimen in relapsed or refractory non - Hodgkin＇ s lymphoma （NHL） . Method： A tottal of 30 relapsed or refractory NHL patients received a course of GMEP regimen, Gemcitabine （GEM） 1000mg/m^2 iv d1-5 .MIT VD - 16 PDV Repeat every 3 - 4weeks.Results： All the patients completed chemotherapy. The follow - up rate was 93.3 % with a median survival duration of 11.3 months. The 1 - year and 2 - year survival rates were 43.3%, 30.8%, respectively.Total responae rate was 80%, with CR for 6 （20%）, PR for 18 （60%）, and 6 in 10 patients were alleviated of type B symptoms.The main adverse effects were myelotoxicity, nauses/vomiting.Conclusion： GMEP regimen can be safely preformed for the patients with relapsed or refractory non - Hodgkin＇ s lymphoma and the shortterm response in comparable to the results of others.